The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11110 malaria professionals are enjoying the free benefits of MalariaWorld today

pyronaridine-artesunate

Pyronaridine-Artesunate (Pyramax) for the Treatment of Artemisinin- and Piperaquine-Resistant Plasmodium falciparum in the Central Highlands of Vietnam

October 5, 2021 - 10:48 -- Open Access
Author(s): 
Manh ND, Thanh NV, Quang HH, Van NTT, San NN, Phong NC, Birrell GW, Edstein MD, Edgel KA, Martin NJ, Chavchich M
Reference: 
Antimicrob Agents Chemother. 2021 Sep 27:AAC0027621

The rise in Plasmodium falciparum resistance to dihydroartemisinin-piperaquine in Vietnam justifies the need to evaluate alternative artemisinin-based combination therapies. Between July 2018 and October 2019, a single-arm trial of pyronaridine-artesunate (Pyramax, PA) was conducted in Dak Nong province, Vietnam. PA (3-day course) was administered to adults and children infected with P. falciparum. PA was well tolerated by the participants. The proportion of patients with Day 42 PCR-corrected adequate clinical and parasitological response was 95.2% (95% confidence interval [CI], 82.3 to 98.8, n = 40/42) for treating falciparum malaria.

Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study

June 16, 2021 - 15:02 -- Open Access
Author(s): 
Tona Lutete G, Mombo-Ngoma G, Ramharter M, et al.
Reference: 
PLoS Med. 2021 Jun 15;18(6):e1003669

In Phase II/III randomized controlled clinical trials for the treatment of acute uncomplicated malaria, pyronaridine–artesunate demonstrated high efficacy and a safety profile consistent with that of comparators, except that asymptomatic, mainly mild-to-moderate transient increases in liver aminotransferases were reported for some patients. Hepatic safety, tolerability, and effectiveness have not been previously assessed under real-world conditions in Africa.

Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial

May 19, 2021 - 13:58 -- Open Access
Author(s): 
Dabira ED, Hachizovu S, Achan J, et al.
Reference: 
Clin Infect Dis. 2021 May 13:ciab425

Pyronaridine-artesunate (PA) is a registered artemisinin-based combination therapy, potentially useful for mass drug administration campaigns. However, further data are needed to evaluate its efficacy, safety and tolerability as full or incomplete treatment in asymptomatic Plasmodium falciparum-infected individuals.

Efficacy and Safety of Pyronaridine-Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar

June 15, 2020 - 15:07 -- Open Access
Author(s): 
Han KT, Lin K, Han ZY, Myint MK, Aye KH, Thi A, Thapa B, Bustos MD, Borghini-Fuhrer I, Ringwald P, Duparc S
Reference: 
Am J Trop Med Hyg. 2020 Jun 8

Four single-arm, prospective, clinical studies of pyronaridine–artesunate efficacy in uncomplicated Plasmodium falciparum or Plasmodium vivax malaria were conducted in Myanmar between 2017 and 2019. Eligible subjects were aged at least 6 years, with microscopically confirmed P. falciparum (n = 196) or P. vivax mono-infection (n = 206). Patients received pyronaridine–artesunate once daily for 3 days with follow-up until day 42 for P. falciparum or day 28 for P. vivax.

Not Open Access | Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017-2018)

May 13, 2020 - 06:42 -- NOT Open Access
Author(s): 
Quang Bui P, Hong Huynh Q, Thi Ta T, et al.
Reference: 
Clinical Infectious Diseases, Volume 70, Issue 10, 15 May 2020, Pages 2187–2195

Multidrug-resistant Plasmodium falciparum undermines the efficacy of currently deployed antimalarial therapies in southern Viet Nam.

NOT Open Access | Pyronaridine-artesunate Shows Promise as an Effective and Well-tolerated Treatment for Artemisinin-resistant Plasmodium falciparum Malaria

May 12, 2020 - 17:51 -- NOT Open Access
Author(s): 
Okombo J, Fidock DA
Reference: 
Clin Infect Dis. 2020 May 6;70(10):2196-2198

Artemisinin-based combination therapies (ACTs) are the recommended first-line antimalarials for uncomplicated malaria and comprise a short-acting artemisinin-based component for rapid reduction of Plasmodium parasite burden partnered with a longer-acting drug to eliminate surviving parasites.

Subscribe to RSS - pyronaridine-artesunate